BMS-931699 Uses, Dosage, Side Effects and more
BMS-931699 is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
| Trade Name | BMS-931699 |
| Generic | Lulizumab pegol |
| Lulizumab pegol Other Names | BMS-931699, Lulizumab pegol |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
